Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Advances Day 2019 | DESTINY update: achieving TFR by de-escalating TKI therapy in CML

Mhairi Copland • 15 Nov 2019
MPN Advances Day 2019
Chronic Myeloid Leukemia Leukemia Dasatinib Imatinib Nilotinib
DESTINY

Mhairi Copland, MB ChB, PhD, Paul O’Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, UK, discusses the DESTINY trial (NCT01804985). This trial aimed to examine the effects of gradual treatment withdrawal and whether TFR is feasible for chronic myeloid leukemia (CML) patients with less deep but stable remission. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

More from Mhairi Copland

3:05
Current and future treatment strategies for blast-phase CML
Mhairi Copland • 29 Sep 2022
1:36
The importance of improving treatment-free remission in patients with CML
Mhairi Copland • 29 Sep 2022
1:12
The challenges associated with long-term TKI use in patients with CML
Mhairi Copland • 29 Sep 2022
2:29
Treatment options for patients with CML
Mhairi Copland • 29 Sep 2022

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals